All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Arbel, 2021 0.10 [0.07; 0.14]
Barda, 2021 0.19 [0.05; 0.70]
McConeghy, 2022 0.03 [0.01; 0.10]
UKHSA report week 12 (24 March 2022), 2022 0.45 [0.19; 1.05]
0.13 [0.05 ; 0.35 ] Arbel, 2021, Barda, 2021, McConeghy, 2022, UKHSA report week 12 (24 March 2022), 2022 4 81% 843,208 low not evaluable deaths (time to event analysis only)detailed results UKHSA report week 12 (24 March 2022), 2022 0.45 [0.19; 1.05]
0.45 [0.19 ; 1.05 ] UKHSA report week 12 (24 March 2022), 2022 1 0% NA not evaluable hospitalization or deathdetailed results Abu-Raddad, 2022 0.23 [0.12; 0.44]
McConeghy, 2022 0.54 [0.23; 1.26]
0.34 [0.15 ; 0.77 ] Abu-Raddad, 2022, McConeghy, 2022 2 59% NA not evaluable clinical deteriorationdetailed results Lauring, 2022 0.44 [0.37; 0.52]
0.44 [0.37 ; 0.52 ] Lauring, 2022 1 0% 11,690 NA not evaluable confirmed COVID (any severity)detailed results Abu-Raddad, 2022 0.51 [0.49; 0.54]
Accorsi, 2022 0.35 [0.33; 0.38]
Bar-On, 2021 0.09 [0.08; 0.10]
C4591031- first boost, 2021 0.05 [0.02; 0.13]
COVI3, 2022 0.07 [0.02; 0.22]
England (Andrews), 2021 0.51 [0.35; 0.76]
Kislaya, 2022 0.31 [0.18; 0.54]
Mattiuzzi, 2022 0.35 [0.32; 0.38]
McConeghy, 2022 0.42 [0.24; 0.74]
Patalon, 2021 0.21 [0.16; 0.28]
Patalon, 2022 0.15 [0.14; 0.17]
South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65]
Southern California (Tseng) - omicron, 2022 0.70 [0.51; 0.95]
Tan, 2022 0.14 [0.05; 0.38]
Tenforde, 2022 0.18 [0.14; 0.23]
Thompson -VISIOn Network (omicron), 2022 0.48 [0.42; 0.54]
0.27 [0.19 ; 0.36 ] Abu-Raddad, 2022, Accorsi, 2022, Bar-On, 2021, C4591031- first boost, 2021, COVI3, 2022, England (Andrews), 2021, Kislaya, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2021, Patalon, 2022, South Africa (Discovery Health, Collie), 2021, Southern California (Tseng) - omicron, 2022, Tan, 2022, Tenforde, 2022, Thompson -VISIOn Network (omicron), 2022 16 99% 148,230 NA low hospitalizationdetailed results Barda, 2021 0.07 [0.04; 0.14]
Lauring, 2022 0.15 [0.13; 0.17]
Mattiuzzi, 2022 0.31 [0.22; 0.44]
McConeghy, 2022 0.52 [0.08; 3.59]
Patalon, 2022 0.08 [0.05; 0.13]
South Africa (Discovery Health, Collie), 2021 0.30 [0.24; 0.38]
Tan, 2022 0.08 [0.01; 0.56]
Tenforde, 2022 0.18 [0.09; 0.35]
Thompson -VISIOn Network (omicron), 2022 0.19 [0.10; 0.36]
0.17 [0.12 ; 0.25 ] Barda, 2021, Lauring, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2022, South Africa (Discovery Health, Collie), 2021, Tan, 2022, Tenforde, 2022, Thompson -VISIOn Network (omicron), 2022 9 86% 398,920 NA not evaluable symptomatic Covid-19detailed results Abu-Raddad, 2022 0.51 [0.49; 0.54]
Accorsi, 2022 0.35 [0.33; 0.38]
COVI3, 2022 0.07 [0.02; 0.25]
England (Andrews), 2021 0.51 [0.35; 0.76]
Kirsebom (UKHSA), 2022 0.76 [0.72; 0.80]
South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65]
Thompson -VISIOn Network (omicron), 2022 0.48 [0.42; 0.54]
0.47 [0.36 ; 0.62 ] Abu-Raddad, 2022, Accorsi, 2022, COVI3, 2022, England (Andrews), 2021, Kirsebom (UKHSA), 2022, South Africa (Discovery Health, Collie), 2021, Thompson -VISIOn Network (omicron), 2022 7 98% 131,448 NA not evaluable ICU admissiondetailed results Mattiuzzi, 2022 0.33 [0.08; 1.36]
0.33 [0.08 ; 1.36 ] Mattiuzzi, 2022 1 0% NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results Bar-On, 2021 0.06 [0.04; 0.10]
Barda, 2021 0.08 [0.03; 0.20]
C4591031- first boost, 2021 0.25 [0.01; 5.50]
Tan, 2022 0.05 [0.03; 0.08]
0.06 [0.05 ; 0.08 ] Bar-On, 2021, Barda, 2021, C4591031- first boost, 2021, Tan, 2022 4 0% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 1.99 [0.07; 59.22]
1.99 [0.07 ; 59.22 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 0.74 [0.17; 3.33]
0.74 [0.17 ; 3.33 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 0.17 [0.01; 3.30]
0.17 [0.01 ; 3.30 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 0.99 [0.06; 15.88]
0.99 [0.06 ; 15.88 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 3.97 [0.18; 88.14]
3.97 [0.18 ; 88.14 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-12 06:25 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290
